PPA
TSHA icon

Parametric Portfolio Associates’s Taysha Gene Therapies TSHA Stock Holding History

Parametric Portfolio Associates’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$123K Buy
+18,928
New +$141K ﹤0.01% 3529
2020
Q4 		– Sell
-13,700
Closed -$307K – 4027
2020
Q3 		$307K Buy
+13,700
New +$322K ﹤0.01% 3474

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Parametric Portfolio Associates's TSHA Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Taysha Gene Therapies (TSHA) in Q1 2022: 18,928 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #3529 among its holdings. This is a return to the name: Parametric Portfolio Associates previously reported a position in TSHA as recently as Q3 2020.

Parametric Portfolio Associates first reported a position in TSHA in Q3 2020 and has held it in 2 quarters since. The position peaked at $307K in Q3 2020. 71 funds tracked by Wall St. Rank hold TSHA as of Q1 2022.

  • Parametric Portfolio Associates held 18,928 shares of Taysha Gene Therapies worth $123K as of Q1 2022.
  • Taysha Gene Therapies was a new Parametric Portfolio Associates position in Q1 2022.
  • Taysha Gene Therapies made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3529 holding.
  • Parametric Portfolio Associates first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 2 quarters since.
  • Parametric Portfolio Associates's Taysha Gene Therapies position peaked at $307K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.